Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19134198 | 0.90 | KMT2A (0.60) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL16082970 | 0.86 | ATF4 (0.82) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL16082952 | 0.86 | ATF4 (0.82) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL19134221 | 0.84 | ATF4 (0.63) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL16082959 | 0.84 | ATF4 (0.63) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL16083047 | 0.84 | ATF4 (1.00) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL16082988 | 0.84 | ATF4 (1.00) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL16082980 | 0.84 | ATF4 (1.00) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL17658570 | 0.82 | MEN1 (0.61) | LMNANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL16082957 | 0.82 | ATF4 (0.76) | ATF4LMNARAB9AHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220477-B2 | Modulators of the eIF2alpha pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-11 | — | — | US | disclosed |
| US-20190240171-A1 | PREVENTIVE AND THERAPEUTIC APPROACH FOR ABERRANT CELL DIFFERENTIATION AND ISR-ASSOCIATED DISEASES | UNIV HONG KONG (CN) | 2019-08-08 | — | — | US | disclosed |
| US-10343981-B2 | Modulators of the eIF2alpha pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-09 | — | — | US | disclosed |
| US-20170342020-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-11-30 | — | — | US | disclosed |
| US-9708247-B2 | Modulators of the eIF2alpha pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160096800-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-04-07 | — | — | US | disclosed |
| WO-2014144952-A2 | MODULATORS OF THE EIF2ALPHA PATHWAY | WALTER PETER (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342020-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | EIF2AK1, EIF2A, EIF2AK3 | ATF4 7/4885LMNA 3251/4885RAB9A 2447/4885 |
| US-11220477-B2 | Modulators of the eIF2alpha pathway | EIF2AK1, EIF2A, EIF2AK3 | ATF4 7/4885LMNA 3251/4885RAB9A 2447/4885 |
| US-20160096800-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | EIF2AK1, EIF2A, EIF2AK3 | ATF4 7/4885LMNA 3251/4885RAB9A 2447/4885 |
| US-10343981-B2 | Modulators of the eIF2alpha pathway | EIF2AK1, EIF2A, EIF2AK3 | ATF4 7/4885LMNA 3251/4885RAB9A 2447/4885 |
| US-20190240171-A1 | PREVENTIVE AND THERAPEUTIC APPROACH FOR ABERRANT CELL DIFFERENTIATION AND ISR-ASSOCIATED DISEASES | ATF4, EIF6, DDIT3 | ATF4 1/4885LMNA 1872/4885RAB9A 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.